Life after cervical cancer: Bowel dysfunction , Urinary dysfunction and quality of life in long-term survivors of carcinoma uterine cervix among In...

Date 24 November 2018
Event ESMO Asia 2018 Congress
Session Poster display - Cocktail
Topics Cervical Cancer
Survivorship
Presenter Niharika Sethi
Citation Annals of Oncology (2018) 29 (suppl_9): ix79-ix86. 10.1093/annonc/mdy436
Authors N. Sethi1, A. Shankar2, J. Patil3, K. Mandrelle4, A. Luther5
  • 1Obstetrics And Gynaecology, Maulana Azad Medical College, 110002 - Delhi/IN
  • 2Preventive Oncology, All India Institute of Medical Sciences, 110608 - NEW DELHI/IN
  • 3Radiation Oncology, Christian Medical College, 141008 - Ludhiana/IN
  • 4Obstetrics And Gynaecology, Christian Medical College, 141008 - Ludhiana/IN
  • 5General Surgery, Christian Medical College, 141008 - Ludhiana/IN

Abstract

Background

Carcinoma cervix is the second most common type of cancer in the world. With the increasing proportion of women surviving carcinoma of the cervix, quality of life has become an important clinical issue.

Methods

The study was prospective and patients treated between 1995 - 2007 on follow up were included in this study after ethical approval. A total of 85 patients were accrued, comprising 6 stage IB, 6 stage II A, 25 stage II B, 2 stage IIIA, 45 stage III B and 1 stage IV A disease. 66 patients were treated with radiotherapy The mean patient age was 47.81 years with a range of 25-68 years. Statistical analysis was performed on a total of 85 patients who were interviewed for late effects of treatment using LENT- SOMA scale.

Results

Average subjective bowel score was seen to be highest in the 40-49 years age group (0.5256) and stage IIA (0.4710) patients. Average subjective bladder score was seen to be highest in the 60-69 years age group (0.5466) and stage IIIB (0.5564) patients. Average subjective scores for both bowel and bladder were highest in the group receiving surgery plus chemo-radiotherapy. The average subjective bowel (0.4557) and bladder (0.5882) scores were highest in the pelvic field with boost group and 2 field group.

Average overall general symptom score was highest in patients who were treated in 1995 (p value- 0.229). Average overall LENT SOMA scale was higher in stage IIIB patients in comparison to stage IB and IIB (p – 0.023 and 0.004, respectively). Average overall LENT SOMA scale was higher in pelvic field when compared to extended field (p – 0.044). Average overall LENT SOMA score was higher in the surgery followed by chemoradiotherapy group and in patients treated by 2 fields.

Conclusions

The LENT SOMA system was acceptable and useful to give an insight into the late morbidity associated with multimodality therapy, especially those presenting at advanced stage. Since it is one of the few studies in India, it will also help us to develop effective management plans to reduce post treatment discomfort and improve quality of life.

Editorial acknowledgement

I would like to warmly thank Dr Abhishek Shankar for giving this opportunity , his professionalism and support.

Clinical trial identification

Legal entity responsible for the study

Dr Abhishek Shankar.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.